267 related articles for article (PubMed ID: 24964073)
1. Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature.
Kreutle V; Blum C; Meier C; Past M; Müller B; Schütz P; Borm K
Swiss Med Wkly; 2014; 144():w13979. PubMed ID: 24964073
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.
Henley D; Kaye J; Walsh J; Cull G
Intern Med J; 2005 Dec; 35(12):726-8. PubMed ID: 16313549
[TBL] [Abstract][Full Text] [Related]
3. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract][Full Text] [Related]
4. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.
Body JJ; von Moos R; Niepel D; Tombal B
BMC Urol; 2018 Sep; 18(1):81. PubMed ID: 30236112
[TBL] [Abstract][Full Text] [Related]
5. Hypocalcemia Secondary to Zoledronate Therapy in a Patient With Low Vitamin D Level.
Epperla N; Pathak R
WMJ; 2015 Aug; 114(4):163-6; quiz 167. PubMed ID: 26436186
[TBL] [Abstract][Full Text] [Related]
6. Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern.
Kaur U; Chakrabarti SS; Gambhir IS
Curr Drug Saf; 2016; 11(3):267-9. PubMed ID: 27113952
[TBL] [Abstract][Full Text] [Related]
7. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
Gulley JL; Wu S; Arlen PM; Dahut WL
Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
[TBL] [Abstract][Full Text] [Related]
8. [Zoledronate-associated end stage renal failure and hypocalcaemia].
Ramazzina C; Zysset Aschmann Y; Kummer O; Rätz Bravo AE; Bodmer M
Praxis (Bern 1994); 2007 Apr; 96(17):673-6; quiz 677-8. PubMed ID: 17491196
[TBL] [Abstract][Full Text] [Related]
9. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
Zuradelli M; Masci G; Biancofiore G; Gullo G; Scorsetti M; Navarria P; Tancioni F; Berlusconi M; Giordano L; Santoro A
Oncologist; 2009 May; 14(5):548-56. PubMed ID: 19411682
[TBL] [Abstract][Full Text] [Related]
10. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
Huynh AL; Baker ST; Stewardson AJ; Johnson DF
Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
[TBL] [Abstract][Full Text] [Related]
11. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
Dave V; Chiang CY; Booth J; Mount PF
Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
[TBL] [Abstract][Full Text] [Related]
12. Hypocalcaemia after denosumab in older people following fracture.
Chen J; Smerdely P
Osteoporos Int; 2017 Feb; 28(2):517-522. PubMed ID: 27682248
[TBL] [Abstract][Full Text] [Related]
13. A case of denosumab-induced hypocalcaemia in a patient with non-metastatic prostate cancer and renal impairment.
Blackley S; Anderson K; Berg J
J R Coll Physicians Edinb; 2015; 45(2):133-5. PubMed ID: 26181529
[TBL] [Abstract][Full Text] [Related]
14. Hypercalcaemia-induced acute kidney injury in an older patient with osteoporosis treated with alfacalcidol for denosumab-induced hypocalcaemia.
Yamada S; Matsuo M; Tokumoto M; Ooboshi H
Nephrology (Carlton); 2017 Jul; 22(7):572-573. PubMed ID: 28621008
[No Abstract] [Full Text] [Related]
15. Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients.
Bird ST; Smith ER; Gelperin K; Jung TH; Thompson A; Kambhampati R; Lyu H; Zhao H; Zhao Y; Zhu Y; Easley O; Niak A; Wernecke M; Chillarige Y; Zemskova M; Kelman JA; Graham DJ
JAMA; 2024 Feb; 331(6):491-499. PubMed ID: 38241060
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature.
Maalouf NM; Heller HJ; Odvina CV; Kim PJ; Sakhaee K
Endocr Pract; 2006; 12(1):48-53. PubMed ID: 16524863
[TBL] [Abstract][Full Text] [Related]
17. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
DE Iuliis F; Taglieri L; Amoroso L; Vendittozzi S; Blasi L; Salerno G; Lanza R; Scarpa S
Anticancer Res; 2014 May; 34(5):2477-80. PubMed ID: 24778063
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate-related atypical femoral fracture with bone metastasis of breast cancer: case report and review.
Hayashi K; Aono M; Shintani K; Kazuki K
Anticancer Res; 2014 Mar; 34(3):1245-9. PubMed ID: 24596367
[TBL] [Abstract][Full Text] [Related]
19. Severe hypocalcemia associated with zoledronic acid treatment in a patient with a risk of fracture due to drug-induced osteopenia.
Cure E; Yuce S; Cure MC
Minerva Endocrinol; 2013 Jun; 38(2):217-8. PubMed ID: 23732377
[No Abstract] [Full Text] [Related]
20. Acute phase response and mineral status following low dose intravenous zoledronic acid in children.
Munns CF; Rajab MH; Hong J; Briody J; Högler W; McQuade M; Little DG; Cowell CT
Bone; 2007 Sep; 41(3):366-70. PubMed ID: 17574945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
